Search the Newsreel

NextCure stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and a $20.00 price target for NextCure Inc. (NASDAQ: NXTC) following investor enthusiasm surrounding its announced reverse merger with Avere Therapeutics. The combined entity will operate as Avere Therapeutics and trade as AVRX, with the transaction expected to …

Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants

Affinity Asset Advisors, along with its managing member Michael Cho, has disclosed a 6.4% beneficial ownership stake in NextCure, Inc. (NXTC) as of June 30, 2026. This stake includes 274,073 shares, with 232,113 shares issuable upon the exercise of warrants, which are subject to …

Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership

Adage Capital Management, L.P. and its affiliates have reported a 7.67% passive ownership stake in NextCure, Inc. (NXTC) through a Schedule 13G filing. The investment firm beneficially owns 277,202 shares of NextCure's common stock, based on 3,612,096 shares outstanding as of May 1, 2026. …

Simcere Zaiming sells $184,800 of NextCure stock

Simcere Zaiming, Inc. sold 30,000 shares of NextCure, Inc. (NASDAQ:NXTC) common stock for $184,800 on August 10, 2026, leading to their exit as a beneficial owner of more than 10% of NextCure. This transaction occurred as NextCure announced a merger agreement with Avere Therapeutics …

Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership

Simcere Zaiming, Inc., and related entities, sold 30,000 shares of NextCure, Inc. common stock at $6.16 per share on August 10, 2026. This transaction reduced their indirect holdings to 308,636 shares. As a result of this sale, the Simcere group is no longer a …

RTW Bio's Avere To Merge With NextCure

(RTTNews) - RTW Biotech Opportunities Ltd. (RTW.L) on Wednesday announced that its private portfolio company Avere Therapeutics agreed to merge with NextCure Inc. (NXTC) in an all-stock transaction. The transaction is expected to close by year-end. The combined company will operate as Avere Therapeutics …

NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis

NextCure (NXTC) plans reverse merger with Avere and $820M financings

NextCure, Inc. (NXTC) and Avere Therapeutics are planning an all-stock reverse merger, with the combined entity to operate as Avere Therapeutics, Inc. and trade on Nasdaq under "AVRX." Avere announced a new $500 million private placement, in addition to a previously disclosed $320 million …

Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics

Xcellon Biologics has acquired a GMP biologics manufacturing facility from NextCure, Inc., transforming it into an end-to-end Contract Research, Development and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics. This acquisition integrates capabilities from discovery through clinical supply and strengthens U.S. biomanufacturing. Abhishake …

Exco Technologies Limited 2026 Q3 - Results - Earnings Call Presentation (TSX:XTC:CA) 2026-08-07

Exco Technologies Limited (3XT) Q4 2024 Earnings Report - Results, Call & Slides

NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for NextCure Inc (NXTC), detailing its current earnings forecast score, average price target of $18.00, and analyst ratings. Based on two analysts, the stock has a "Buy" recommendation with a potential upside of over 200%. The article also …

NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk

NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger

NextCure, Inc. (Nasdaq: NXTC) announced its second-quarter 2026 financial results, reporting a net loss of $14.9 million, an improvement from $26.8 million in Q2 2025. The company also detailed its definitive all-stock merger agreement with Avere Therapeutics, which includes a concurrent private financing for …

NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary

NextCure, Inc. reported a significantly narrower net loss in Q2 2026, with net income at $(14.9)M or $(2.80) EPS, compared to $(26.8)M or $(11.29) EPS in the prior year. This improvement comes as the company pursues a strategic pivot through a proposed merger with …

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

NextCure, Inc. announced its business update and second quarter 2026 financial results, including details on its proposed merger with Avere Therapeutics. The merger is an all-stock transaction, with Avere expected to raise $320 million in private financing, and NextCure stockholders receiving contingent value rights …

NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4

NextCure Inc. has detailed a two-step merger plan with Avere Therapeutics, Inc., as per an agreement dated July 14, 2026. This complex merger will involve two subsidiary mergers to ultimately make Avere a wholly-owned subsidiary of NextCure. NextCure plans to file a Form S-4 …

ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million

ADAR1 Capital Management, a 10% owner of NextCure, has reported the open-market purchase of 329,153 common shares of NextCure, valued at approximately $3.59 million. The buying prices were between $4.8 and $5 per share, increasing ADAR1's indirectly held stake to 722,419 common shares. Daniel …

Exco Technologies Limited XTC Earnings Miss Estimates by 15.0%

Form 4 NextCure Inc For: 4 August By Investing.com

This article from Investing.com reports on a Form 4 filing for NextCure Inc. for August 4th. The filing indicates insider transactions, which are legally required disclosures of changes in stock ownership by company insiders. The article itself is a brief announcement without further details …

Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares

ADAR1 Capital Management, LLC, a 10% owner of NextCure, Inc. (NASDAQ:NXTC), purchased 329,153 shares of NextCure common stock for over $1.6 million on July 30 and 31, 2026. This insider buying occurred while NextCure's stock was down, and the company recently announced a merger …

ADAR1-managed funds buy 329,153 shares of NextCure (NXTC)

Private investment funds managed by ADAR1 Capital Management, LLC, which may be associated with Daniel Schneeberger, purchased a total of 329,153 shares of NextCure (NXTC) common stock on July 30-31, 2026. These transactions occurred at weighted-average prices generally between $4.7563 and $5.0000. The purchases …

Exco Technologies Limited (XTC) Q2 2024 Earnings Report - Results, Call & Slides

Key Points Interested in Exco Technologies Limited? Here are five stocks we like better. Exco Technologies posted record Q3 fiscal 2026 sales of CAD 165.4 million, up 7% year over year, while EBITDA rose 26% to CAD 18.5 million. The consolidated EBITDA margin improved …

NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC

This article provides a basic overview of NextCure, Inc. (NASDAQ: NXTC) financial information available on TradingView. It indicates that the market for NXTC is currently closed and no trades are occurring. The page serves as a portal for accessing various financial data points, including …

Exco Technologies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

NXTC|NextCure Inc|Price:4.145|Chg%:-0.885

NextCure Inc. (NXTC) is trading at $4.145, down 17.59%. Despite recent strong performance, analysts expect a medium-term downtrend. The company, a clinical-stage biopharmaceutical firm focusing on cancer treatments, holds a "Buy" rating from two analysts with a target price of $17.50.

Adar1 capital management increases NextCure (NXTC) stake by $87,712

ADAR1 Capital Management, a 10% owner of NextCure Inc. (NASDAQ:NXTC), has increased its stake in the biotechnology company by purchasing 17,608 shares for a total of $87,712. These transactions occurred between July 27 and July 29, 2026, at prices ranging from $4.9496 to $5.0000 …

NextCure Inc (NXTC) Institutional Confidence

NextCure Inc (NXTC) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 48.41%, showing a 43.46% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.70% of …

NextCure's Maryland Operation Winds Down in Reverse Merger With San Francisco-Based Avere Therapeutics

NextCure, a Beltsville-based immuno-oncology company, has announced an all-stock merger with San Francisco-based Avere Therapeutics, a privately held biotech focusing on inflammatory diseases. The deal will result in NextCure's workforce reduction and the shelving of its pipeline, with pre-merger NextCure stockholders owning approximately 1.21% …

Form 4 NextCure Inc For: 29 July By Investing.com

This article reports on the filing of Form 4 by NextCure Inc. for July 29, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they buy or sell shares of their …

ADAR1-managed funds add 17,608 NextCure (NASDAQ: NXTC) shares

ADAR1 Capital Management, LLC and Daniel Schneeberger, as 10% owners of NextCure, Inc. (NASDAQ: NXTC), reported open-market purchases of 17,608 shares of common stock. These shares were bought by ADAR1-managed private investment funds between July 27 and July 29, 2026, at prices ranging from …

NextCure files Form 3 initial beneficial ownership statement for ADAR1 Capital Management

NextCure has filed a Form 3 disclosing ADAR1 Capital Management as a 10% owner, with indirect beneficial ownership of 375,658 common shares. Daniel Schneeberger was also reported as a 10% owner in the same filing. The filing event date was July 27, 2026, and …

NextCure Inc (NXTC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for NextCure Inc (NXTC), noting its current valuation score of 7.58, which ranks 198 out of 385 in its industry. The company's P/E ratio is -0.32, significantly below its recent high but above its recent low. Key valuation …